Drug Profile
ETI 210
Alternative Names: ETI-210Latest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Complement activation stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 20 Apr 2022 EluSys Therapeutics has been acquired by Heat Biologics
- 04 Jul 2005 Data presented at the BIO 2005 Annual International Convention (BIO-2005) have been added to the adverse events and Cancer pharmacodynamics section
- 09 May 2005 EluSys Therapeutics has completed preclinical studies in Non-Hodgkin's lymphoma